Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01617967 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01617967 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT01617967, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This was a multiple dose, dose escalation study designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
Interventions
- DRUG Patisiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01617967
The ClinicalTrials.gov registry entry for NCT01617967 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patisiran is the first listed.
NCT01617967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01617967 about?
NCT01617967 is a clinical study titled "Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis". This was a multiple dose, dose escalation study designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
What is the current status of trial NCT01617967?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2012-05. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01617967?
The interventions under investigation include: Patisiran (DRUG).
Who is sponsoring clinical trial NCT01617967?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.